Tumour necrosis factor soluble receptors I and II and interleukin-1 receptor antagonist in acute pyelonephritis in relation to bacterial virulence-associated traits and renal function

Nephrology Dialysis Transplantation

Volumn 11, Issue 11, 1996, Pages 2209-2214

  Jacobson, S H ^a   Lu, Y ^a   Brauner, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute pyelonephritis; Cytokine receptors; Interleukin 1; Renal function; Tumour necrosis factor; Urinary tract infection

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE PYELONEPHRITIS; ADOLESCENT; ADULT; AGED; ARTICLE; ASYMPTOMATIC BACTERIURIA; BACTERIAL VIRULENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; CYTOTOXICITY; ESCHERICHIA COLI; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY CELL; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; URINARY TRACT INFECTION;

EID: 0029953436     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027138     Document Type: Article

References (22)

1. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106-113
2. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-4849
3. Fleischman JD, Wentworth DB, Thomas KM, Imbembo AL. Urinary interleukin-2 inhibition in patients with cystitis, Immunol Invest 1989; 18: 825-831
4. Jacobson SH, Hylander B, Wretlind B, Brauner A. Interleukin-6 and interleukin-8 in serum and urine in patients with acute pyelonephritis in relation to bacterial-virulence-associated traits and renal function. Nephron 1994; 67: 172-179
5. Svanborg C, Agace W, Hedges S, Lindstedt R, Svensson ML. Bacterial adherence and mucosal cytokine production. Ann NY Acad Sci 1994; 730: 162-181
6. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-357
7. Dinarello CA, Thompson RC. Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro, Immunol Today 1991; 12: 404-410
8. Fischer E, Marano MA, Van Zee KJ et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli shock but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551-1557
9. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-1536
10. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilisation of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-329
11. Jacobson SH, Källenius G, Lins L-E, Svenson SB. P-fimbriated Escherichia coli in adults with acute pyelonephritis. J Infect Dis 1985; 152: 426-427
12. Jacobson SH, Tullus K, Brauner A. Hydrophobic properties of Escherichia coli causing acute pyelonephritis. J Infect 1989; 19: 17-23
13. Brauner A, Katouli M, Tullus K, Jacobson SH. Production of cytotoxic necrotizing factor, verocytotoxin and haemolysin by pyelonephritogenic Escherichia coli. Eur J Clin Microbiol Infect Dis 1990; 9: 762-767
14. Digel W, Porszolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukaemia and type B chronic lymphocytic leukaemia. J Clin Invest 1992; 89: 1690-1693
15. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure. CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896
16. Rugo HS, O'Hanley P, Bishop AG et al. Local cytokine production in a murine model of Escherichia coli pyelonephritis. J Clin Invest 1992; 89: 1032-1039
17. Zemel D, Imholz ALT, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-α and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46: 1422-1430
18. Froon AHM, Bemelmans MHA, Greve JW, van der Linden CJ, Buurman WA. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome, correlation with plasma creatinine values. Crit Care Med 1994; 22: 803-809
19. Engelberts I, Stephens S, Francot GJ, van der Linden CJ, Burman WA. Evidence for different effects on soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338: 515-516
20. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150: 2007-2017
21. Tullus K, Escobar-Billing R, Fituri O et al. Interleukin-1 α and interleukin-1 receptor antagonist in the urine of children with acute pyelonephritis and relation to renal scarring. Acta Paediatr 1996; in press
22. Cannon JG, Tompkins RG, Gelfland GA et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84